
References

Key Findings in AML: An Overview with Eytan M. Stein, MD

Perl AE, Cortes JE, Strickland SA, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. *J Clin Oncol*. 2018;35(15):TPS7067.

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS7067

DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *N Engl J Med*. 2018;378:2386-2398.

<https://www.nejm.org/doi/full/10.1056/NEJMoa1716984>

Cortes JE, Heidel FH, Heuser M, et al. A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. *Blood*. 2016;128:Abstract 99.

<http://www.bloodjournal.org/content/128/22/99?sso-checked=true>

Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 with Mark J. Levis, MD, PhD

Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. *Blood*. 2018;132(6):598-607.

<http://www.bloodjournal.org/content/132/6/598.long?sso-checked=true>

Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2018;19(7):889-903.

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(18\)30240-7/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30240-7/fulltext)

Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML with Eytan M. Stein, MD

Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. *Blood*. 2017:blood-2017-04-779405.

<http://www.bloodjournal.org/content/early/2017/06/05/blood-2017-04-779405?sso-checked=true>

Abstracts

Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 with *Mark J. Levis, MD, PhD*

Cortes J, Khaled S, Martinelli G, et al. Quizartinib Significantly Prolongs Overall Survival in Patients with FLT3-Internal Tandem Duplication–Mutated (Mut) Relapsed/Refractory AML in the Phase 3, Randomized, Controlled QUANTUM-R Trial. EHA23: 2018. Abstract LB2600.

https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html?f=ce_id=1346*ot_id=19045*media=3

Strategies for Achieving Durable Responses in Elderly AML Patients with *Keith W. Pratz, MD*

DiNardo CD, Pratz K, Potluri J, et al. Durable Response with Venetoclax in Combination with Decitabine or Azacitadine in Elderly Patients with Acute Myeloid Leukemia (AML). EHA23: 2018. Abstract: S1563.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214482/courtney.d.dinardo.durable.response.with.venetoclax.in.combination.with.html?f=ce_id=1346*ot_id=19045*media

Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML with *Eytan M. Stein, MD*

Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (MIDH2) Acute Myeloid Leukemia (AML). EHA23: 2018. Abstract S1561.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214480/daniel.a.pollyea.enasidenib.monotherapy.is.effective.and.well-tolerated.in.html?f=ce_id=1346*ot_id=19045*media=3

Stein EM, Stone RM, Pollyea DA, et al. Continuing Enasidenib Treatment for Patients with Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Responses and Survival Over Time. EHA23: 2018. Abstract PS980.

https://learningcenter.ehaweb.org/eha/2018/stockholm/215305/eytan.m.stein.continuing.enasidenib.treatment.for.patients.with.mutant-idh2.html?f=ce_id=1346*ot_id=19045*media=3

Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML with *Jorge E. Cortes, MD*

Cortes J, Medeiros B, Uy G, et al. Outcomes by Number of Induction Cycles with CPX-351 Versus 7+3 Chemotherapy in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (SAML). EHA 2018. Abstract PF239.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214725/jorge.cortes.outcomes.by.number.of.induction.cycles.with.cpx-351.versus.72B3.html?f=ce_id=1346*ot_id=19045*media=3

Baer M, Watts J, Lee S, et al. A Phase 1 Dose Escalation Study of the IDH1M Inhibitor, FT-2102, in Patients with Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS). EHA 2018. Abstract PF236.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214722/maria.baer.a.phase.1.dose.escalation.study.of.the.idh1m.inhibitor.ft-2102.in.html?f=ce_id=1346*ot_id=19045*media=3